Rigel Pharma (RIGL) to Commence Development of R343
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reports the it will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials.
Pfizer Inc. is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.
Pfizer Inc. is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and expects to design a Phase 2 clinical trial with R343 later this year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evolus (EOLS) Reports Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau
- Montrose Environmental (MEG) Announces Pricing of Public Offering of Shares
- Oracle (ORCL) to Invest More Than $8 Bln in Cloud Computing and AI in Japan
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
